Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.

Oncogene - 25 Sept 1997

Hui R, Campbell D H, Lee C S, McCaul K, Horsfall D J, Musgrove E A, Daly R J, Seshadri R, Sutherland R L

Abstract excerpt

Chromosome 11q13 is amplified in about 13% of primary breast cancers. CCND1, encoding the cell cycle regulatory gene cyclin D1, and EMS1, encoding a filamentous actin binding protein, are favoured candidate onocogenes, whereas INT-2 is an unexpressed gene at this locus. In this study we tested th...

Topics

Breast Neoplasms
Chromosomes, Human, Pair 11
Cortactin
Cyclin D1
Fibroblast Growth Factor 3
Fibroblast Growth Factors
Gene Amplification
Genetic Markers
Humans
Microfilament Proteins
Neoplasm Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phenotype

Proto-Oncogene Proteins

Source

Identifiers

PMID: 9380415
DOI: 10.1038/sj.onc.1201311

Genes

CCND1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9380415-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.PMID 9380415Read ↗

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.Semantic proximity Read ↗

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.Semantic proximity Read ↗

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assaysSemantic proximity Read ↗

Functional characterization of EMSY gene amplification in human cancersSemantic proximity Read ↗

Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinomaSemantic proximity Read ↗

PPFIA1 and CCND1 are frequently coamplified in breast cancer.Semantic proximity Read ↗

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerSemantic proximity Read ↗

Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancerSemantic proximity Read ↗

EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalSemantic proximity Read ↗

High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.Semantic proximity Read ↗

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.Semantic proximity Read ↗

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.